MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

STERIS PLC

Slēgts

SektorsVeselības aprūpe

226.43 1.03

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

223.02

Max

227.26

Galvenie mērījumi

By Trading Economics

Ienākumi

16M

173M

Pārdošana

42M

1.4B

P/E

Sektora vidējais

35.174

57.333

EPS

2.32

Dividenžu ienesīgums

1.03

Peļņas marža

12.643

Darbinieki

18,000

EBITDA

-85M

245M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+17.08% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.03%

2.63%

Nākamie ieņēmumi

2025. g. 14. maijs

Nākamais dividenžu datums

2025. g. 25. jūn.

Nākamais Ex dividenžu datums

2025. g. 11. jūn.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

21B

Iepriekšējā atvēršanas cena

225.4

Iepriekšējā slēgšanas cena

226.43

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

STERIS PLC Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. febr. 21:35 UTC

Peļņas

Steris: Outlook Does Not Reflect Any Potential Impact From New Tariffs >STE

2025. g. 5. febr. 21:34 UTC

Peļņas

Steris: FY25 Guidance Change Is Primarily Due to Currency >STE

2025. g. 5. febr. 21:34 UTC

Peļņas

Steris Cuts FY25 Revenue View to Increase of About 6% From Prior View for 6.5%-7%>STE

2025. g. 5. febr. 21:33 UTC

Peļņas

Steris 3Q EPS $1.75 >STE

2025. g. 5. febr. 21:30 UTC

Peļņas

Steris Sees FY Adj EPS $9.05-Adj EPS $9.15 >STE

2025. g. 5. febr. 21:30 UTC

Peļņas

Steris 3Q Rev $1.4B >STE

2025. g. 5. febr. 21:30 UTC

Peļņas

Steris 3Q Adj EPS $2.32 >STE

2024. g. 6. nov. 21:41 UTC

Peļņas

Steris Backs FY25 Revenue Up 6.5%-7.5% >STE

2024. g. 6. nov. 21:40 UTC

Peļņas

Steris 2Q EPS $1.51 >STE

2024. g. 6. nov. 21:30 UTC

Peļņas

Steris Sees FY Adj EPS $9.05-Adj EPS $9.25 >STE

2024. g. 6. nov. 21:30 UTC

Peļņas

Steris 2Q Adj EPS $2.14 >STE

2024. g. 6. nov. 21:30 UTC

Peļņas

Steris 2Q Rev $1.3B >STE

2024. g. 6. aug. 20:36 UTC

Peļņas

Steris 1Q Adj EPS $2.03 >STE

2024. g. 6. aug. 20:30 UTC

Peļņas

Steris 1Q Net $139.9M >STE

2024. g. 6. aug. 20:30 UTC

Peļņas

Steris 1Q EPS $1.41 >STE

2024. g. 6. aug. 20:30 UTC

Peļņas

Steris Sees FY Adj EPS $9.05-Adj EPS $9.25 >STE

2024. g. 3. jūn. 11:03 UTC

Iegādes, apvienošanās, pārņemšana

PEAK ROCK Cap Affil COMPLETES PREVIOUSLY ANNOUNCED ACQUISITION of HUFRIEDYGROUP

2024. g. 31. maijs 20:47 UTC

Iegādes, apvienošanās, pārņemšana

Steris Completes $787.5M Sale of Dental Segment to Peak Rock Capital

2024. g. 8. maijs 20:40 UTC

Peļņas

Steris Sees FY25 Adj EPS $9.05-Adj EPS $9.25 >STE

2024. g. 8. maijs 20:39 UTC

Peļņas

Steris: Plan Includes Restructuring of the Healthcare Surgical Business in Europe >STE

2024. g. 8. maijs 20:39 UTC

Peļņas

Steris Announcing a Targeted Restructuring Plan >STE

2024. g. 8. maijs 20:39 UTC

Peļņas

Steris 4Q EPS $3.81 >STE

2024. g. 8. maijs 20:30 UTC

Peļņas

Steris 4Q Adj EPS $2.58 >STE

Salīdzinājums

Cenas izmaiņa

STERIS PLC Prognoze

Cenas mērķis

By TipRanks

17.08% augšup

Prognoze 12 mēnešiem

Vidējais 265 USD  17.08%

Augstākais 265 USD

Zemākais 265 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi STERIS PLC — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

224.01 / 229.01Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par STERIS PLC

STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.